William Blair Issues Positive Estimate for NAMS Earnings

Key Points

• William Blair upgraded its earnings estimates for NewAmsterdam Pharma, projecting a Q3 2025 EPS of ($0.32), an increase from a previous estimate of ($0.52).
• NewAmsterdam Pharma's share price recently opened at $25.31, with a market cap of $2.84 billion and an average target price estimated at $41.20 among analysts.
• Institutional investors hold 89.89% of NewAmsterdam Pharma's stock, indicating strong institutional interest in the company amidst recent performances.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Analysts at William Blair increased their Q3 2025 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a research note issued to investors on Wednesday, August 6th. William Blair analyst M. Phipps now expects that the company will earn ($0.32) per share for the quarter, up from their previous forecast of ($0.52). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma's Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.54) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.

Other analysts have also recently issued reports about the company. Stifel Nicolaus started coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Citigroup assumed coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price target on the stock. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS traded down $0.97 during mid-day trading on Monday, hitting $24.80. 329,765 shares of the stock were exchanged, compared to its average volume of 875,526. The company has a market cap of $2.78 billion, a PE ratio of -15.31 and a beta of -0.02. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The firm has a 50-day moving average of $21.09 and a two-hundred day moving average of $20.06.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in shares of NewAmsterdam Pharma during the first quarter worth about $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $50,000. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after acquiring an additional 596 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after acquiring an additional 3,390 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, COO Douglas F. Kling sold 100,000 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer owned 44,000 shares in the company, valued at approximately $848,760. This trade represents a 69.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director James N. Topper purchased 8,584 shares of the business's stock in a transaction dated Monday, June 16th. The shares were purchased at an average price of $19.50 per share, for a total transaction of $167,388.00. Following the purchase, the director owned 3,022,153 shares of the company's stock, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 12,835 shares of company stock worth $248,134 and have sold 198,612 shares worth $4,025,887. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.